Hagens Berman investigation launched into Madrigal Pharmaceuticals over whistleblower clinical data integrity claims
Hagens Berman announced an investigation into Madrigal Pharmaceuticals following a whistleblower complaint filed in October 2026 alleging suppressed liver-injury data, efficacy discrepancies, and improper board oversight of Rezdiffra clinical trials. The firm is examining whether executives misrepresented data integrity and regulatory compliance.
Why it matters. Investors who suffered losses in MDGL securities are encouraged to submit information; the investigation could lead to regulatory action or securities litigation affecting the stock and the drug's market position.